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Abstract
Monoclonal antibodies are commercially important, high value biotherapeutic drugs used in the treatment of a variety of
diseases. These complex molecules consist of two heavy chain and two light chain polypeptides covalently linked by
disulphide bonds. They are usually expressed as recombinant proteins from cultured mammalian cells, which are capable of
correctly modifying, folding and assembling the polypeptide chains into the native quaternary structure. Such recombinant
cell lines often vary in the amounts of product produced and in the heterogeneity of the secreted products. The biological
mechanisms of this variation are not fully defined. Here we have utilised experimental and modelling strategies to
characterise and define the biology underpinning product heterogeneity in cell lines exhibiting varying antibody expression
levels, and then experimentally validated these models. In undertaking these studies we applied and validated biochemical
(rate-constant based) and engineering (nonlinear) models of antibody expression to experimental data from four NS0 cell
lines with different IgG4 secretion rates. The models predict that export of the full antibody and its fragments are
intrinsically linked, and cannot therefore be manipulated individually at the level of the secretory machinery. Instead, the
models highlight strategies for the manipulation at the precursor species level to increase recombinant protein yields in
both high and low producing cell lines. The models also highlight cell line specific limitations in the antibody expression
pathway.
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Introduction
Mammalian cell lines have been used industrially for several
decades for the production of complex, high value recombinant
therapeutic proteins. They are preferred over other expression
systems largely because of their ability to correctly fold, assemble
and undertake the required post-translational modifications that
decorate recombinant proteins of eukaryotic origin [1,2]. Biother-
apeutics produced in mammalian expression systems include
recombinant monoclonal antibodies (mAbs) [2] and plasma
proteins [1]. As the demand for such protein based therapies has
increased, so have the yields obtained from mammalian expression
systems, with current product yields more than a 100-fold greater
than those achieved 20–30 years ago [2,3,4]. Most of this increase
in yield has come through improvements in culture media
composition and feeding regimes [2], and/or via improved
screening strategies to identify cell lines that obtain and maintain
higher biomass [5].
An alternative to improving biomass yield or viable cell
concentration is to enhance the cell specific productivity (or
amount of product produced per cell per unit time, qP).
Approaches to improve qP include direct cell engineering (see
below), culture additives (e.g. sodium butyrate [6]), or manipula-
tion of the culture environment (e.g. change in culture temper-
ature [7,8]). The cellular mechanisms by which such approaches
improve qP are poorly understood.
There have been various approaches investigated to improve
the cell specific productivity of mammalian cell lines by direct
manipulation of the cellular machinery itself, for example by
over-expression or knockdown of specific targets [9]. Particular
targets investigated to date with a view to improving qP in
mammalian cell lines include anti-apoptotic genes [10,11,12,13],
cell cycle related genes [14,15,16], the folding and assembly
machinery in the endoplasmic reticulum [17,18,19,20,21,22],
and the translational [23,24,25] and secretory machinery [26].
However, such approaches to improving qP in mammalian cell
lines have largely resulted in conflicting or disappointing results.
While these attempts at manipulating the cellular machinery are
based upon our knowledge of the general requirements for, and
bottlenecks in, protein synthesis and secretion in mammalian
cells, we do not currently have a complete understanding of the
recombinant gene expression pathway and the intricate interac-
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tions between the various cellular processes that are required to
work in symphony to give and define a highly productive
recombinant cell line.
In the specific case of monoclonal antibodies produced from
mammalian cells, a number of groups have attempted to define
the limitations upon their cell specific production (qmAb), and
hence identify rational targets for cell engineering, using ‘omic’
profiling of cell lines exhibiting differing qmAbs
[27,28,29,30,31,32,33,34,35,36]. These studies have largely
focussed on either transcriptomic or proteomic profiling, and
generally show that there are many cell line specific differences in
gene expression activity that correlate with qmAb. Moreover,
there are specific classes or families of proteins that also correlate
with qmAb in their expression levels. A problem with interpret-
ing these studies is the difficulty in deciding whether observed
changes in gene expression are the result of high qmAb,
underpin high qmAb, or are a non-specific consequence of the
various cellular processes that show changes in gene expression
correlating with qmAb. As such, whilst these studies have
furthered our understanding of cellular processes that underpin
high qmAb, they have generally not been able to clearly define
these processes, nor to quantify their individual contribution to
antibody expression.
Another approach to identifying cellular constraints upon
qmAb by which engineering strategies could be devised and
validated is to use model-based approaches [37]. Such approaches
can consider the whole gene expression pathway and the
contribution of the different cellular processes to it, allowing both
the identification of cellular bottlenecks, and the prediction of how
engineering strategies or manipulation of specific steps might
impact upon qmAb. A small number of such studies have now
shown the proof of concept of such an approach [4,38,39]. Indeed,
we have previously used a luciferase model system to show that the
quantitative determination of gene expression intermediates can
be a powerful tool for analysing cell-line specific limitations in gene
expression pathways [40]. Here we set out to apply the same
strategy to analysing the expression of a model IgG4 antibody.
Antibodies are the fastest growing group of the high-value
biopharmaceuticals [41], and have a complex gene expression
pathway that involves the synthesis of two heavy and two light
chain polypeptides, followed by folding of the polypeptide chains,
assembly into the tetrameric antibody structure, and secretion of
the final product.
There are four subclasses of the IgG isotype (IgG1–4) and the
folding and assembly of the IgG1 and IgG2 isotypes have been
described in some detail (e.g. see [42]. However, the folding
pathway(s) of the IgG4 isotype is currently not well characterised.
Moreover, antibody secretion is usually accompanied by the
secretion of contaminant folding intermediates and off-pathway
by-products, and we wished to understand the relationship
between the productive and non-productive pathways in more
detail. Here we describe the measurement of key parameters
throughout the IgG4 gene expression pathway in NS0 cells of
varying productivity, and then use this information and our
knowledge of the synthesis, folding and assembly pathways of IgGs
to develop models that describe the gene expression pathway and
the limitations upon this in four different NS0 cell lines. We
subsequently validated these models by successfully predicting
qmAb for a naive cell line. Our models highlight the cell line
specific nature of limitations on qmAb but also highlight potential
engineering approaches to remove cellular limitations upon gene
expression.
Results
We investigated four recombinant GS-NS0 cell lines which are
engineered to express a chimeric cB72.3 IgG4 molecule and which
had previously been shown to exhibit different qmAbs [35]. These
cell lines were grown under batch culture conditions as described
in the methods section. We initiated the study by analysing which
polypeptide and protein intermediates of the antibody folding
pathway were observable in our cell lines using a western blotting
approach. For sampling we chose a time point 96 hours after
seeding of the cells during mid-exponential growth phase (Fig. 1A).
Up to this point in culture, growth rate, cell viability and
productivity of each of the four cell lines investigated was constant
and these parameters did not start to decline until approximately
120 h of batch culture. The combination of constant growth rate
and constant productivity at the sampling point suggests that the
cells are internally in a steady state (File S1). This is consistent with
many published modelling studies relying on the same assumption
[4,10,11,12,38,43].
When analysing intracellular material from the four cell lines by
western analysis (with qmAbs (molecules*cell21*h21) as follows:
2N2–2.66106, 2P –0.46106, 4O –0.16106 and 4R – ,0.16106)
we could distinguish a number of bands which reacted with a
polyclonal anti-human IgG whole antibody, consisting of a
mixture of heavy and light chain species specific antibodies
(Fig. 1B). In order to maintain model fidelity only bands which
could be clearly assigned to a given antibody species were used in
model construction. A fully assembled antibody consists of two
heavy and two light chains held together by disulphide bridges,
and probing with the individual heavy- and light-chain antibodies
allowed us to unambiguously identify 2 major and 3 minor bands
(Fig. 1B), in agreement with other western analysis of the IgG4
cB72.3 molecule [30,44]. These bands correspond to full antibody
(LHHL where L = light chain and H = heavy chain), half-
antibody (HL), free heavy- (H) and free light- (L) chain, and light-
chain dimer (LL). In the cell-culture supernatant western blotting
using the polyclonal anti-human IgG whole antibody identified
four species that corresponded to full and half antibody, free light
chain, and light chain dimer (Fig. 1B and File S2). It was obvious
even from this simple analysis that there were differences in the
abundance of the species present between the cell lines.
The data shown in Fig. 1B indicate the relative abundance of
the species observed at the sampling time point. Additional
monitoring of the change in abundance of the different
supernatant species over time allowed us to assign secretion rates
for each of these, and to compare secretory activity in our cell lines
to previously published data ([4,38,43], Fig. 2). We conclude from
this analysis that both in terms of secretion of the fully formed
monoclonal antibody, and of the two major by-products (free light
chain L and light-chain dimer LL), the secretion parameters lie
within the range reported by others for IgG secretion from
mammalian and insect cells and hence represent an appropriate
model set. Further, this analysis confirmed that the four cell lines
cover a range of qmAb values (Fig. 2) that would facilitate our
modelling studies.
In the supernatant we also observed a species which we
identified as half-antibody based on its apparent molecular weight
and its reactivity with anti-heavy and anti-light chain antibodies
(File S3). Intracellularly this species is a potential antibody
assembly intermediate, however in the supernatant it is considered
a by product [45]. O’Callaghan et al. also observed this species in
CHO cells, and initially ascribed this to the reductive decay of full
antibody into two half-molecules [4]. In a more recent study they
suggest this is generated as a result of a slow rate of redox recycling
Recombinant Antibody Production in NS0 Cells
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of half antibody into full antibody within the ER [46]. However, in
contrast to the situation in CHO cells, we did not observe any
change in the half-antibody: full-antibody ratio if our samples were
treated with different reducing agents that would prevent Fab arm
exchange (Fig. 3A). Moreover, this ratio did not change upon
prolonged incubation of purified antibody at room temperature
(Fig. 3B), making it unlikely that in our case this species arose as
the result of a decay process. On the other hand, the abundance of
this species in the supernatant was dependent on the general
cellular export activity (see analyses below), and we therefore
conclude that in our NS0 cell lines, half-antibody is exported from
the cell in a similar manner to the other three supernatant species.
IgG4 antibodies undergo Fab arm exchange reactions [45,47]
and we note that although this species in the supernatant appears
as a half-antibody of 75 kDa molecular weight on denaturing
SDS-PAGE gels, it may not be exported in this form. Gel filtration
experiments conducted on isolated antibodies show that under
non-denaturing conditions this species elutes with an apparent
molecular weight of 150 kDa (data not shown) [44]. This indicates
that in solution the IgG4 half-molecule (HL) actually exists as non-
covalently bound full antibody and it is likely that this species is
exported in this form. Indeed, the inter-heavy chain disulfide
bonds of IgG4 have been reported to be in equilibrium with intra-
chain disulfide bonds resulting in some of the IgG4 having non-
covalently linked heavy chains [48]. The levels of this species were
reported to be expression system dependent and this may explain
why much lower levels of half antibody for the same IgG4 were
reported when expressed in CHO cells as in the study of
O’Callaghan [4] compared to our observations in NS0 cells.
Following the basic characterisation of observable species in the
supernatant, we determined absolute levels of observable intra-
cellular protein intermediates by quantitative western blotting and
comparison against a standard of purified full-length antibody and
antibody-fragments of known concentrations (Table 1 and File
S2). Such an approach has previously been demonstrated to be
accurate for quantitatively determining protein levels [49].
Absolute amounts of heavy and light chain mRNA were also
determined using qRT-PCR using in vitro-transcribed mRNA as a
quantitative reference (Table 1). The steady state levels showed a
large excess of light chain mRNA compared to heavy chain
mRNA in all cell lines, but this was not reflected at the polypeptide
level where the amount of intracellular heavy chain, and of light
chain and light chain dimer (LL) combined, were of a similar
magnitude (Table 1).
In our previous analyses [40], we combined steady-state
abundance data such as those determined here with information
on turnover rate constants to form the basis for a comprehensive
characterisation of a simple gene expression pathway. In the case
of monoclonal antibodies, the determination of turnover rate
constants is difficult because, upon inhibition of translation, the
existing species are processed by a number of pathways including
protein turnover, formation of higher-order complexes, and
export. Consequently, we observed that when we inhibited
translation by addition of cycloheximide, the abundance of
individual species changed with complex rates that could not be
fitted to simple first- or second-order rate constants (data not
shown). The information on our antibody-producing cell-lines is
thus limited to steady-state abundance of intracellular species and
to secretion rates. Given this limited information, we decided to
investigate how far in silico modelling approaches could assist the
characterisation of antibody expression pathways in the different
cell lines.
In defining our mathematical models we considered reports that
IgGs can assemble via two principal routes, either by formation of
a half-antibody intermediate (HL) from which the full antibody is
assembled via the association of two HL molecules (‘‘HL’’ pathway
where H = heavy chain polypeptide and L = light chain
polypeptide, H-.HL-.(HL)2), or by the initial formation of a
heavy-chain dimer to which then sequentially recruits two light
chains (‘‘HH’’ pathway, H-.H2-.H2L-.H2L2) [42,50]. The
assembly pathways for several murine IgGs have been elucidated
and predominantly proceed through the HH pathway for IgG1
and IgG2a, and the HL pathway for IgG2b and IgM [42]. Sears
and colleagues also suggested that whilst these might be the major
Figure 1. Antibody-related species detected by western
analysis in the different cell lines. A. Example growth curve of
cell line 2N2. A sampling point was chosen below the maximum viable
cell concentration, where cell-specific productivity was observed to be
stable. (Full growth curves are available in File S1) B. The different
species that could be observed in intracellular or supernatant samples
were identified by western blotting with a polyclonal antibody able to
detect both heavy chain and light chain species. The species are (from
top) assembled antibody (LHHL), half antibody (LH), single heavy chain
(H), light chain dimer (LL) and single light chain (L). For clarity of species
observation intracellular and supernatant blots are representative and
not of the same exposure time, quantitative data was obtained by
western blotting alongside internal standards and is given in Table 1.
Full data tables are provided in File S5.
doi:10.1371/journal.pone.0047422.g001
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pathways for assembly, it was possible that assembly occurred via
concurrent pathways [50]. Despite such studies, there is no
definitive work yet published on the assembly routes of chimeric
antibodies (such as the cB72.3 antibody in this study), human
antibodies, or IgG4 antibodies in general. Our observations of
species levels did not allow us to unambiguously define which
assembly pathway was utilised in our cell lines and we therefore
modelled the two potential assembly pathways independently
(Fig. 4) alongside a combined model.
Table 1. Summary of experimentally determined parameters.
2N2 2P 4O 4R
Steady state
levels
H.RNA 781 250 71 137
molecules*cell21
L.RNA 60611 41165 741 550
H 4.76106 2.56106 ,0.16106 2.36106
L 1.76106 1.46106 1.16106 1.46106
LL 1.26106 0.86106 0.76106 0.56106
HL 1606106 606106 106106 .0.16106
HH ,0.16106 ,0.16106 ,0.16106 ,0.16106
LHH ,0.16106 ,0.16106 ,0.16106 ,0.16106
LHHL 126106 2.66106 1.46106 2.36106
secretion rates
qL 376106 1.66106 0.46106 ,0.16106 molecules
*cell21*h21
qLL 126106 1.06106 0.16106 ,0.16106
qmAb 2.96106 0.46106 0.16106 ,0.16106
qHL 116106 0.76106 0.16106 ,0.16106
rate constants Growth 0.020 0.025 0.036 0.025 h21
H.RNA decay ,0.025 0. 400 0.038 0.043
L.RNA decay ,0.025 0.109 0.026 0.026
H = heavy chain; L= light chain.
doi:10.1371/journal.pone.0047422.t001
Figure 2. Comparison of productivity in the current model system with other reported expression systems. Secretion rates observed in
the cell lines used in this study are compared to a number of published rates for various eukaryotic expression systems [4,38,43]. L (light chain), LL
(light chain dimer), mAb (assembled monoclonal antibody).
doi:10.1371/journal.pone.0047422.g002
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The two models we used contain 11 (‘‘HL’’) and 13 (‘‘HH’’)
abundance parameters, respectively, as well as 19 (‘‘HL’’) and 23
(‘‘HH’’) rate parameters (Fig. 4 and File S3). We were able to
experimentally determine all but two of the abundance parame-
ters, and placed upper limits on the two undetectable species (HH
and HHL in the ‘‘HH’’ model). In contrast, we only determined
five rate parameters directly (the productivity or ‘‘q’’ parameters
for the four exported species, and the growth rate). In normal
modelling terms, this limited number of determined rate
parameters could mean that the models are strongly under-
determined. In order to deal with the paucity of parameters, we
used two independent modelling approaches based either on
systems of classic biochemical pathways, or on approaches
optimised for use in the engineering field. Both models use
systems of differential equations, detailed in File S3, as underlying
descriptions of the model structure and are defined by the MatLab
source code given in File S4.
For the biochemical rate-based model, we avoided complica-
tions resulting from the experimentally undetermined rate
constants by using a single simplifying assumption, namely that
intracellular protein turnover was negligible compared to the flux
of molecules along the antibody assembly pathway. This
assumption is likely to introduce only a small error into the
model: for example, a recent study that investigated ubiquitination
of the different mAb polpypeptide species in CHO cells found that
only ubiquitinated full antibody was observed, that this accounted
for only 0.3% of the total assembled antibody, and that the
secretory machinery beyond the ER was not saturated [46]. This
suggests that very little antibody or assembly intermediates are
targeted for degradation and supports the use of this assumption
here.
In assuming that there is zero recombinant polypeptide/protein
turnover, the entire outflow of mass from the system is thereby
given by the q-values of the four exported species and by the
dilution through growth i.e. by the five experimentally determined
rates. Following the laws of mass conservation, the molecular flux
through all of the other branches of this model can then be
accurately calculated. Apparent rate constants for all reactions can
be calculated by dividing the steady-state fluxes through the
observed steady-state levels of the respective intermediates. With
the resulting parameters, this model reproduces observed steady-
state values accurately.
In order to validate this approach, we also made use of
alternative modelling techniques from the domain of control
engineering. In the systems biology discipline it is usually assumed
that mathematical models do not perfectly represent reality.
Indeed, even in cases where high fidelity models are available, it is
acknowledged that external factors will change parameters and
external disturbances will affect the model. A key issue therefore
becomes that of robustness i.e. ensuring that the system response is
minimally sensitive to any perturbations in parameters of the
model. In the engineering model developed to describe the NS0
cell lines, the possible interconnections between all parameters
were implemented as a linear state matrix augmented with a gain
matrix distributing the nonlinear interconnections within the
system. Unknown rate constants for HH and HL models were
determined via least squares fitting at steady-state conditions and
the best-fitting parameter sets applied to our models. Residual
plots of the difference between experimentally observed parameter
values vs. those defined by the models show only very small
differences, indicating that resulting models can reproduce
experimental observations for all four cell lines robustly (Fig. 4).
However, the course of the analysis established that the two
models were highly ill-conditioned, with a conditioning number of
1010, meaning that parameter estimates have the potential to be
very sensitive to small changes in the estimated rate constants. The
combined model, in which HH and HL pathways are allowed to
coexist, had a higher conditioning number of 1014, and in this case
pseudo inversion was used to define the unknown parameters [51].
It was possible to determine rate constants consistent across the
three models, with the results from the independent ‘HH’ and
‘HL’ sub-models being used to verify the findings for the combined
model.
In terms of validating the sensitivity of the parameterisation to
changes in the assumed steady-state, the performance of the model
was investigated at steady-state conditions ‘close’ to those
measured experimentally, where a 10% change in steady-state
conditions was assumed. Other tests were also carried out at
steady-state conditions far from the measured conditions (where a
100% change was assumed). The characteristics of the model
behaviour were preserved and the model was found to be robust to
changes in both the assumed steady-state and the parameter
estimates.
Figure 3. Origin of the HL species. A. Treatment of 2N2 samples
with oxidising agents does not alter the ratio of half-antibody to full
mAb. BMDB (1,4-bismaleimidyl-2,3-dihydroxybutane), NEM (N-ethylma-
leimide), LHHL (assembled antibody), LH (half antibody species), LL
(light chain dimer), L (light Chain). B. In cell culture supernatants the
ratio of half- to full antibody does not change upon prolonged
incubation at room temperature. Both analyses indicate that the half
antibody species does not result from decay of the full antibody.
doi:10.1371/journal.pone.0047422.g003
Recombinant Antibody Production in NS0 Cells
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For both assembly pathways, we tuned the models to reproduce
our experimentally observed steady-state abundance nearly
perfectly (Fig. 4). Detailed parameter values are given in Table 2.
It should be noted that the rate constants emerging from our
models are pseudo-first order constants which group together
many detailed rate constants from the complex reactions occurring
during real antibody assembly, and they therefore have limited
meaning in a true biological sense. However, as we show below,
they can be subsequently be used for meaningful analyses. They
are also useful for comparisons with previous modelling studies
assuming similar pathways. In general, the rates we determine for
the HH model are similar to rates previously inferred for
experimental CHO cell data fitted to a HH-like assembly pathway
[4], with the exception of addition of light chains to the heavy
chain dimer, for which our models predict faster reactions than the
CHO model (Table 2). In our model such high rates are required
to take account of the fact that the HH and HHL intermediates
could not be observed experimentally. At the fitted rates, the
assembly reaction can proceed via this pathway with intermediate
levels below their experimental detection limit of ,105 molecules
per cell (derived from the experimentally determined detection
limit for full antibodies). Thus, we conclude that our observed
steady state values are consistent with IgG4 assembly via either of
the two suggested assembly routes, or with a mixed assembly
involving the two routes combined in any proportion.
We then used the models to derive the relative flux of material
through the different branches of the antibody expression and
assembly pathway (shown for the HL model in Fig. 5). Especially
when fluxes are normalised to the qmAb of the different cell lines,
it becomes apparent that the relative proportion of unproductive
export (L, LL and HL species) to productive export (mAb) remains
remarkably constant between cell lines of different productivity
(shown for the HL pathway in figure 5, but similarly observed with
the HH pathway models). This finding would be consistent with all
species being exported via a common, non-selective export
mechanism, which processes the intracellular species strictly
according to their abundance. The ratio of exported species in
this scenario is determined by the ratio of free intracellular heavy-
and light-chains. This would agree with other studies that have
suggested that mAb secretion does not exert a significant limitation
upon mAb productivity and that the secretory machinery is not
saturated beyond the ER and able to adjust to fluxes in the
amount of mAb [4,46].
Since the four cell lines studied here differ significantly in the
mAb secretion rates (qmAb), we used the models to investigate
whether any of the intracellular parameters are closely linked to
this primary parameter. We assessed the similarity in the patterns
with which all model parameters occur across the different cell
lines by means of clustering analyses. Clustering was based on the
correlation coefficients between the different parameter sets,
meaning that parameters cluster together if they are highly
correlated between the different conditions analysed. Results from
this analysis for the HL and HH models are shown in figure 6. In
both versions of the model, antibody secretion or qmAb (the
primary parameter of interest) forms a cluster with all other
secretion rates, as well as with parameters from the later stages of
the intracellular assembly process. In contrast, parameters from
earlier stages of the assembly process do not tend to fall into this
Figure 4. The fit of our models to the observed steady-state values determined experimentally. Different antibody assembly models
were fitted to the different observed steady-state data given in Table 1. Panels on the left-hand side (A and C) show the assembly routes for the two
different models, with productive reactions (those leading to the formation of full antibody) displayed in red. The panels on the right-hand side (B
and D) indicate the difference between the best-fitting parameter set in the biochemical models and the observed parameter values. The two
models, as well as a model combining the two assembly pathways, can all reproduce the experimentally observed data for all four cell-lines with high
similarity. Similar results were obtained for the engineering models. H.mRNA (heavy chain mRNA), L.mRNA (light chain mRNA), LHHL (assembled
antibody), LH (half antibody species), H (heavy chain), HH (heavy chain dimer), HHL (heavy chain dimer +1 light chain), LL (light chain dimer), L (light
Chain), mAb (assembled secreted antibody), qmAb (mAb secretion rate), qHL (HL secretion rate), qLL (LL secretion rate), qL (L secretion rate).
doi:10.1371/journal.pone.0047422.g004
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cluster. The sole exception to this rule is the H-translation rate,
which appears linked to the qmAb parameter in both the HL and
HH model versions (Fig. 6). In summary, these findings indicate
that a high qmAb is most likely to occur in cell lines where
secretion rates for other species, as well as rates in the late
assembly stages, are also high.
We observe an interesting difference in clustering between
‘‘secretion’’ and ‘‘export’’ parameters for individual species. The
secretion parameters (qmAb, qL etc) are essentially zero-order rate
constants that describe the constant export of molecules as a
function of the cell type. In contrast, the export parameters are
apparent first-order rate constants that describe export as a
function of the intracellular abundance of the exported species.
The qmAb, mAb export, qL, L export, qLL, LL export and qHL
parameters are all located within the same cluster, in other words,
they have a tendency to show similar patterns across the different
cell lines. In contrast, the ‘‘HL export’’ parameter is not part of
this cluster. This indicates that HL export is functionally unlinked
from the abundance of intracellular HL, and may instead be
linked to other export activities of the cell. This is further evidence
that HL may not actually be exported as HL but rather as non-
covalently bound intact antibody but which is observed as an HL
molecule under SDS-PAGE conditions as described above.
The clustering analysis further indicates that of those intracel-
lular parameters that are amenable to manipulation, heavy-chain
translation is the one that is most closely linked to qmAb. In all cell
lines investigated total light chain polypeptide produced differs
owing to differing transcript levels, however the number of times
each individual light chain transcript is translated per hour
remains relatively stable between cell lines of varying productivity
(Table 2). In contrast, our models show that in addition to differing
heavy chain transcript levels the highest producing 2N2 cell line
uses each heavy chain transcript for several more rounds of
translation per hour than the lower producing cell lines. Thus, if
one wished to maximise qmAb and minimise secretion of other
species, this would be the most promising parameter to
manipulate. In order to explicitly test this prediction in our
models we systematically altered heavy-chain translation rates and
followed the predicted change in secretion rates for the four
secreted species (in our models, an increase in heavy-chain mRNA
or in heavy-chain translation has the same effect). For comparison,
we performed the same exercise for variations in light-chain
production rates. Results from both the biochemical and
engineering models predict that increasing light-chain production
rates will simply lead to an increase in non-productive qL and
qLL, while leaving qHL and qmAb largely unaffected (Fig. 7). In
contrast, increasing heavy-chain production is predicted to
favourably affect qmAb over the other secretion rates.
The analyses presented so far indicate that both biochemical
and engineering-type models are useful to derive information
about complex gene expression pathways with limited information
on relevant parameters. As a further modelling exercise, we asked
whether we could use the engineering model for types of analysis
that are classically used in control engineering, but which are not
frequently used in the biosciences. A case in point is observability
analysis, which effectively investigates if a mapping exists linking
the external output(s) of a system directly to all the internal states
of the system. This observability testing was conceived by Kalman
in the early 1960s [52]. We used this principle to ask whether all
thirteen parameters currently under consideration were in-fact
required to infer qmAb, or whether a subset of these parameters
could be sufficient to predict this parameter. This analysis thus has
the potential to simplify and focus future experimental campaigns
as well as refining models.
Table 2. Summary of apparent rate constants.
2N2 2P 4O 4R
Reported range
in CHO cells [4]
All models
m Growth rate 0.020 0.025 0.036 0.025 0.025–0.035
K1 H.RNA transcription 15.6 107 5 9 38–670 molecules* hour
21
K2 H.RNA turnover 0 0.4 0.038 0.043 0.09–0.11 hour
21
K3 L.RNA transcription 1214 5486 46 28 82–1222 molecules* hour
21
K4 L.RNA turnover 0 0.1 0.026 0.026 0.03–0.06 hour
21
HL model
K5 H translation 37565 13193 12042 2007 n/a molecules* RNA
21* hour21
K8 L translation 1498 169 2140 1129 n/a molecules* RNA
21* hour21
K7 H + L 2. HL 3.5610
26 9.161027 1.561025 8.261028 n/a molecule21* hour21
K10 L + L 2. LL 8.5610
26 1.061026 2.561027 1.061027 n/a molecule21* hour21
K16 HL + HL 2. LHHL 8.9610
210 8.9610210 8.9610210 8.9610210 n/a molecule21* hour21
HH model
K5 H translation 37884 7521 8615 827 331–2154 molecules* hour
21
K8 L translation 1502 170 2213 2141 431–1513 molecules* hour
21
K10 L + L 2. LL 8.5610
26 161026 2.561027 161027 10210–1029 molecule21* hour21
K19 H + H 2. HH 5.1610
27 1.261027 6.161025 2.661028 1027–1021 molecule21* hour21
K21 HH + L 2. HHL 6.5 0.49 0.13 0.09 10
26–1025 molecule21* hour21
K22 HHL + L 2. LHHL 6.5 0.49 0.13 0.09 10
26–1025 molecule21* hour21
H = heavy chain; L= light chain.
doi:10.1371/journal.pone.0047422.t002
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We therefore developed a linearised version of the model, based
on linerisation in the region of the steady-state operating point. A
series of step response tests were performed which demonstrated
good correlation between the behaviour of the linear and
nonlinear models. This linear model contained the same number
of parameters as the nonlinear counterpart, but had a reduced
requirement for parameters that needed to be known to predict
qmAb. Observability testing demonstrated that it was possible to
determine qmAb from nine rather than the original 13 param-
eters, all of these being abundance parameters for intracellular
species. The engineering analysis thus supports a paradigm that
qmAb can be inferred from a reduced set of parameters, which are
accessible by sampling at a single time point.
To validate the results from the observability analyses, we tested
whether models parameterised with a reduced parameter set could
predict qmAb of a cell line not previously used in the construction
of the model. We used an NS0 cell line (2X) which had been
generated at the same time and from the same parental cell line as
the four cell lines used in the construction of the model [35].
Judged by the experimentally determined qmAb, this cell line is a
mid producer, in between the 2N2 and 2P cell lines described
earlier. When the experimentally determined levels of the
Figure 5. Comparison of pathway fluxes as a function of productivity. The molecular flux through individual reactions was obtained from
the biochemical models running at steady state. The colour of the arrows connecting the model species indicates the molecular flux from one species
to the next in molecules per time unit. The left hand panel show absolute pathway fluxes for three cell lines. The right hand panel shows relative
fluxes, normalised to the highest individual reaction flux observed for each cell line. The diagrams shown are for the ‘‘HL’’ assembly pathway. H.mRNA
(heavy chain mRNA), L.mRNA (light chain mRNA), LHHL (assembled antibody), LH (half antibody species), H (heavy chain), HH (heavy chain dimer),
HHL (heavy chain dimer + 1 light chain), LL (light chain dimer), L (light Chain), mAb (assembled secreted antibody).
doi:10.1371/journal.pone.0047422.g005
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Figure 6. Clustering analysis of cell-line specific parameters. Parameters were obtained from the biochemical models at steady state for each
of the four cell lines analysed. Parameters that occur in similar patterns across the different cell lines are closely clustered in this analysis. Statistically
significant clusters containing the qmAb parameter are indicated in red. H.mRNA (heavy chain mRNA), L.mRNA (light chain mRNA), LHHL (assembled
antibody), LH (half antibody species), H (heavy chain), HH (heavy chain dimer), HHL (heavy chain dimer +1 light chain), LL (light chain dimer), L (light
Chain), mAb (assembled secreted antibody).
doi:10.1371/journal.pone.0047422.g006
Figure 7. Predicted intervention points for the reduction of by-product export. The predicted effect of variations in increased heavy- (left
panel) or light-chain (right panel) expression is illustrated. While variations in light chain expression predominantly affect secretion of the L and LL by-
product species, variation in heavy chain expression selectively affects the expression of fully formed antibody. qmAb (assembled antibody secretion
rate), qHL (half antibody secretion rate), qLL (light chain dimer secretion rate), qL (light chain secretion rate).
doi:10.1371/journal.pone.0047422.g007
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intracellular intermediates for this cell line were used to
parameterise the derived linear model, a qmAb value was
predicted of 3.36105 molecules per cell per hour, an order of
magnitude lower than the experimentally determined value of
0.96106 molecules per cell per hour (Table 3). In contrast, when
the reduced parameter set was used to parameterise the original
non-linear model, a qmAb value was predicted of 0.9–16106
molecules per cell per hour, very close to the experimentally
determined value. These results indicate that, while the linearised
model was not in itself useful for predicting qmAb, it was useful for
exploring dynamic system properties and allowed us to simplify the
parameterisation strategy for the full non-linear antibody produc-
tion model. Overall, this result validates the general modelling
strategy, and demonstrates that engineering-type models can be
used to predict properties of cell lines beyond those used to
generate the training data for model construction.
Discussion
The detailed characterisation of recombinant protein expression
systems is essential for understanding differences between expres-
sion cell lines and for the rational design of consistent and stable
high producers. While this characterisation is relatively straight-
forward for single-protein products [40], it is complicated for
products with more complex assembly pathways such as mono-
clonal antibodies. Indeed, due to our limited understanding of
mAb antibody assembly in industrially relevant cells for different
IgG isotopes, it is currently not possible to fully define the
limitations upon mAb production and develop cell engineering
strategies based upon the analysis of the gene expression pathway
to enhance the ability of these systems to synthesise, assemble and
secrete antibodies. In this study, we have developed and
investigated modelling approaches to describe the gene expression
pathway of a model mAb and as a tool to define cell engineering
strategies to improve qmAb or as a means of identifying observers
of high producing cell lines.
Modelling approaches have been used in the past for the
characterisation of antibody assembly pathways [4,38,43]. These
studies made predictions with respect to the most likely assembly
routes and points of control within the system. An emerging theme
from these studies is that limitations are exerted in a heterogeneous
manner depending on the cell line in question. For example,
O’Callaghan et al. found that mRNA transcription, mRNA
stability, folding of assembly intermediates, and secretion rates
could all fully or partially limit qmAb in CHO isolates exhibiting
different productivity [4]. Our studies agree with these previous
analyses, showing cell line specific limitations whilst also
highlighting specific parameters that could be used as observers
to predict and screen for cell lines capable of high cell specific
productivity. Indeed, given such heterogeneity of control, the
rational design of consistently super-expressing cell lines is clearly a
difficult problem and as suggested by O’Callaghan and colleagues
likely to be cell line specific [4].
In order to model the IgG4 synthesis and assembly pathway we
had to consider two potential assembly routes for IgGs. There
have been no definitive experimental reports describing the
assembly of IgG4 molecules. Although the HH model had
previously been suggested as the most likely assembly route [4],
our experimental data did not allow us to unambiguously identify
the assembly pathway in our system. Indeed, our observed steady
state values were consistent with IgG4 assembly via either of the
two suggested assembly routes, or with a mixed assembly involving
the two routes combined in any proportion, as both models could
be tuned to reproduce our experimentally observed steady-state
data. This suggests that the assembly process itself, and the
different chaperones and folding requirements for each of these
pathways, are unlikely to be the major limiting determinants in
qmAb production.
Recent studies have shown that manipulation of the secretion
machinery within recombinant cell lines can increase cell specific
secretion rates [26,53,54,55]. O’Callaghan et al. reported that the
rate of mAb secretion varied widely across a panel of CHO cell
lines, and although this did not correlate with qmAb, they
suggested secretory engineering as a possible cell line specific
engineering approach [4]. Our modelling data are consistent with
the fully assembled IgG4 molecule (LHHL) and the off target
species (L, LL, HL) all being exported via a common, non-selective
export mechanism, which processes the intracellular species strictly
according to their abundance. As a result, our data and models
predict that any strategies to improve secretion would result in the
increased secretion of off target species in addition to the fully
assembled molecule, and that the ratio of exported species would
remain the same.
The ratio of active product to inactive by-products is an
important expression system parameter as it determines the
downstream processing behaviour of antibody-based therapeutics.
An alternative strategy suggested by our modelling studies is to
manipulate points earlier in the pathway by altering the ratio of
free intracellular heavy- and light-polypeptide chains. Model
derived translation rates identified that the highest producing cell
line utilises each heavy chain transcript several fold more times per
hour than in the lower producing cell lines and in-silico
experiments using our model predict increased productivity in
all cell lines by increasing heavy chain translation rates. The
differential usage of heavy chain transcripts by the highest
producing cell line suggests possible cell specific optimisation of
the complex cellular translation machinery. In contrast to
manipulating secretory activity directly, optimisation of the ratio
of free intracellular heavy- and light-chains is predicted to increase
Table 3. Summary of observed parameters for the additional
naı¨ve 2X cell line.
2X
Steady state
levels
H.RNA n.m.
molecules*cell21
L.RNA n.m.
H 4.26106
L 2.06106
LL ,0.16106
HL 7.36106
HH ,0.16106
LHH ,0.16106
LHHL 3.76106
secretion
rates
qL 2.26106 molecules
*cell21*h21
qLL 3.26106
qmAb 0.96106
qHL 0.96106
rate constants Growth 0.019 h21
doi:10.1371/journal.pone.0047422.t003
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qmAb specifically whilst reducing the secretion of the undesirable
off target products (qLL and qL, Fig. 7).
Finally, we applied engineering principles to our models in the
form of observability analysis in order to indentify a minimum set
of parameters required to define cell lines with high qmAb. Our
analyses suggest that qmAb may be fully predictable from
measurements of a reduced set of solely intracellular species, and
we demonstrated the validity of this approach experimentally. In
conclusion, modelling approaches can be used to both identify
high-producing cell lines and to manipulate the gene expression
machinery with the aim of further improving productivity.
Methods
Experimental
Cell lines and cell culture. The four mouse myeloma (NS0)
cell lines used in this study, which are stably expressing IgG4 mAb
cB72.3 with glutamine synthetase as a selectable marker, have
been described previously 35]. The cell lines were generously
provided by Lonza Biologics plc (Slough, UK) and were routinely
cultured as previously described 19]. For time course studies n= 9
E250 flasks (n = 3 control, n = 3 cycloheximide treatment and
n=3 actinomycin D treatment flasks) were seeded at 0.26106 cells
mL21 in a 50 ml culture volume and maintained as suspension
cultures at 36.5uC, 5% CO2 and 100 rpm. Cell samples were
taken daily for supernatant analysis to determine qMab values and
cell counts performed using a Vi-CELL 1.01 (Beckman Coulter,
High Wycombe, UK). At mid-exponential phase (96 h post-
inoculation) cells were harvested and mRNA and protein analysis
undertaken for final model parameterisation as described below.
In Vitro Transcription of HC and LC mRNA. For in vitro
transcription of HC and LC mRNA, primers were designed to
either side of the region of interest with a T7 promoter sequence
added on the forward primer. Amplification of HC and LC
fragments was performed by standard PCR using High Fidelity
Taq polymerase (Roche, Burgess Hill, UK) with the following
amplification protocol; 95uC for 5 min, followed by 35 cycles of
95uC for 30 s, 55uC for 30 s and 72uC for 1 min, with a final
extension at 72uC for 10 min. PCR products were subsequently
gel purified and used as a template in T7 RiboMax Express large
scale RNA production system (Promega, Southampton, UK).
Following transcription, template DNA was removed by DNase1
digestion and the RNA product purified using an RNeasy mini kit
(Qiagen Ltd). Integrity of the transcription product was verified on
denaturing polyacrylamide gels.
RNA Extraction and Quantitative Real Time PCR. Total
RNA was extracted from NS0 cell lines using the RNeasy
extraction kit (Qiagen Ltd, UK) with on-column DNAse treatment
according to the manufacturer’s instructions. The expression level
of HC and LC mRNA transcripts was determined by use of gene
specific primers and quantitative real time reverse transcription-
PCR (qRT-PCR) as previously described 40]. mRNA quantifica-
tion was carried out using mRNA from n= 3 control samples per
cell line. A standard curve was prepared in duplicate from in vitro
transcribed RNAs in order to calculate actual mRNA levels.
Samples were normalised to the housekeeping gene b-actin and
mRNA copy numbers extrapolated from the standard curve. For
mRNA half-life measurements the transcription inhibitor actino-
mycin D (final concentration 4 mM) was added at T0 to triplicate
biological cultures and relative mRNA levels subsequently
determined after 0, 0.5, 1.2, 2, 2.4, 4 and 6 h and mRNA half-
lives determined as previously described 40].
Cell Extracts and Western Blotting. Intracellular proteins
were prepared in RIPA buffer as described (Harlow and Lane
1988), sonicated (16 mm peak-to-peak, 365 s) and supplemented
with 5x gel loading buffer [56]. Culture supernatants were cleared
by centrifugation at 13000 x rpm for 10 min at 4uC and
supplemented with 5x gel loading buffer. Samples were resolved
by SDS-PAGE on a 10% non-reducing gel and western blotting
was performed using a standard semi-dry method [57]. Detection
of both intracellular and supernatant species were performed using
a rabbit anti-human IgG whole molecule (1:1000), rabbit anti-
human IgG c chain (1:500) from Sigma-Aldrich or goat anti-
human kappa light chain (1:1000) from Bethyl Laboratories
(Montgomery, USA) as indicated within the manuscript. Primary
antibodies were detected using a horse radish peroxidise (HRP)
conjugated goat anti-rabbit IgG antibody (Sigma-Aldrich) or
rabbit anti-goat HRP (Santa Cruz Biotechnology, USA) as
appropriate and visualised using ECL reagent (GE Healthcare
Life Sciences, Little Chalfont, UK). Western blot images were
analysed with the AIDA image analyser software (Raytest Ltd,
UK) and quantification of absolute levels performed as described
[49] using purified IgG4 as a standard.
mAb Species Secretion Rate. Cell specific productivity
(qMab) was calculated using absolute quantification of each mAb
species by western blotting across day 0 to day 4 of culture and the
time integral of viable cells (IVC) [58,59]. Calculations used were.
Average viable cell concentration (VCC)
VCCave~
VCC1zVCC2
2
Change in VCCave between t1 and t2
ðt2
t1
VCC dt~VCCave(t1{t2)
Time integral of viable cells (IVC)
IVC~
ðtfinal
tinitial
VCCdt~
X
t
VCCave(t1{t2)
Cell specific productivity
qMab~
½Mab2{½Mab1
IVC
Stability of the intact IgG4 species during gel electrophoresis was
assessed by addition of the alkylating agent N-ethylmaleimide
(NEM) (20 mM final concentration) or the sulfhydryl-reactive
homobifunctional crosslinker 1,4-bismaleimidyl-2,3-dihydroxybu-
tane (BMDB, Pierce Biosciences) (0.2 mM final concentration) to
both the supernatant and the RIPA buffer immediately after
sample collection. Samples were subsequently analysed by
standard western blotting.
mAb Species Stability. Stability of the ratio of intact IgG4
species to half mAb in culture supernatant was tested by
incubating cleared supernatant in a 37uC sterile environment for
up to 96 h post collection, resolving by SDS-PAGE and detection
by Coomassie blue staining.
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SimBiology model
Implementation. The differential equation systems provided
in File S3 were used to construct a standard biochemical model in
the Matlab Simbiology toolbox (version 2009a, MathWorks,
Cambridge, UK). Details of the model are shown in figure 4A.
The model was parameterised by calculating apparent first order
rate constants from the observed productivity data and levels of
the intracellular species, under the assumption of protein turnover
for these species being negligible compared to the dilution through
cell growth as described in the results section. Models were run
using the standard ode45 (Dormand-Prince) solver with typical
simulation times of 25,000 seconds.
Data Clustering. Apparent first-order rate constants for all
chemical transitions in the system and for each cell-line were
hierarchically clustered using the Matlab clustergram procedure.
Clustering was performed based on Spearman’s rank correlation
relating the parameter sets for each cell line.
Simulink model
Implementation. The engineering model was developed in
Simulink and included all possible interconnections between the
parameters including nonlinear interconnections. Where available,
rate constants were used as determined experimentally. Any
unknown rate constants were determined via simple least squares
fit at steady-state conditions. This latter procedure was carried out
independently for the HH, HL and combined model to provide
information on the likely variation in rate constant to benchmark
the models for robustness. It was possible to determine rate
constants consistent across the three models. Having developed a
nonlinear model, the model was then linearised in the region of the
steady state operating point. A series of step response tests were
performed which demonstrated good correlation between the
behaviour of the linear and nonlinear models. This linear model
contained the same number of parameters as the nonlinear
counterpart.
Observability analysis. Having obtained and validated the
linear model representation, further analysis was undertaken to
infer to what degree a model of lower order could be used to infer
qmAb. The observability testing demonstrated that it is possible to
construct qmAb from nine, rather than the 13 parameters present
in the original model. Step response tests on this reduced order
model correlated well with the step response tests performed on
both the nonlinear and linear models in the region of steady state
operation.
Model Validation. We validated our models with a naive cell
line to determine whether the models could predict the qmAb
from measurement of the parameters suggested by the minimal
observability analysis. We initially estimated K8 using the minimal
parameters measured for the naı¨ve cell line for the HH and HL
models and then for the combined model used a coarse average of
the two estimates. As measurements were not experimentally taken
to enable k1 and k3 to be determined directly, we used the
following equations to determine suitable values from the
measured data;
k1
k2zm
~100
and
k3
k1zm
~3227
The linear model was then generated as before, with the above
assumptions, the new measured data and the previous model. The
observability analysis was carried out on the linear model exactly
as previously described with the intent of identifying the species
that determine the final output. Again the number of observable
states was found to be nine from the naive cell line experimental
results.
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